Rucaparib Camsylate and Radiation Therapy in Treating Patients with Triple Negative Breast Cancer or Hormone Receptor Positive Breast Cancer

Inclusion Criteria

• Female, >= 18 years if age
• Non-metastatic, histologically or cytologically-confirmed triple negative breast cancer (TNBC) (defined as estrogen receptor [ER] < 1%, progesterone receptor [PR] < 1%, her-2-neu 0-1+ by immunohistochemistry [IHC] or fluorescence in situ hybridization [FISH]-negative or as per doctor of medicine [MD] discretion), with evidence of residual disease in the breast or lymph nodes after neoadjuvant chemotherapy, at the time of definitive surgical treatment.
• Non-metastatic, histologically or cytologically-confirmed hormone-receptor positive, Her2/neu negative breast cancer (defined as ER > 1% or PR > 1% AND Her-2/neu 0-1+ by IHC or FISH-negative, or as per MD discretion), with evidence of residual grade 3 invasive breast cancer AND either 1) > 5 cm of residual disease in the breast OR 2) >= 4 axillary lymph nodes (LNs) in the axilla after neoadjuvant chemotherapy, at the time of definitive surgical treatment
• Definitive surgical treatment with breast-conserving surgery or mastectomy and axillary lymph node evaluation.
• At least 6-month life expectancy.
• Eastern Cooperative Oncology Group (ECOG) performance status < 2.
• Willingness to discontinue any cytotoxic chemotherapeutic agents, and biologic therapy at least 2 weeks prior to the start of RT
• Absolute neutrophil count (ANC) >= 1500/mm^3 (within 30 days prior to initiation of protocol treatment)
• Platelet count >= 100,000/mm^3 (within 30 days prior to initiation of protocol treatment)
• Hemoglobin >= 9.0 g/dL (after transfusion if required) (within 30 days prior to initiation of protocol treatment)
• Creatinine serum =< 1.5 mg/dL or creatinine clearance >= 45 mL/min (within 30 days prior to initiation of protocol treatment) * If calculated creatinine clearance is < 45 mL/min, a 24-hour urine collection for creatinine clearance may be performed
• Bilirubin =< 1.5 mg/dL (within 30 days prior to initiation of protocol treatment) * Subjects with documented Gilbert’s disease may have bilirubin up to 2.5 mg/dL
• Aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN) (within 30 days prior to initiation of protocol treatment)
• Alanine aminotransferase (ALT) =< 2.5 x ULN (within 30 days prior to initiation of protocol treatment)
• Negative serum pregnancy test within 14 days prior to study treatment if a woman has child-bearing potential. Subjects of child bearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year.
• Ability to swallow and retain oral medications.
• Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.
• Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the duration of study participation. Should a woman become pregnant while participating on study, she should inform the treating physician immediately.

Exclusion Criteria

• Gross residual tumor on imaging or positive margins after breast conserving surgery that are un-excised, as radiation dose in the study will be limited to 60 Gy
• Complete pathologic response to neoadjuvant chemotherapy (NAC).
• Receipt of PARP inhibitor prior to RT.
• Pregnant or expecting to conceive within the projected duration of the trial, starting with screening visit through 180 days after the last dose of trial treatment.
• Prior history of radiation therapy to the ipsilateral breast and/or regional nodes is not allowed (prior RT to other sites is permitted).
• Patients with breast augmentation are excluded.
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to rucaparib.
• Concomitant anti-neoplastic treatment is not allowed during protocol treatment and should be completed at least 2 weeks prior to commencement of protocol treatment, with resolution of associated acute toxicities. Bisphosphonates are permitted without restriction even during protocol treatment. Maintenance pembrolizumab is permitted during the protocol treatment
• Significant comorbidity: Patients with clinically significant and uncontrolled major disease or disorder that could exacerbate potential toxicities, confound safety assessments, require excluded therapy for management, or limit study compliance.
• Ongoing therapy with other investigational agents. Patients may not be receiving any other investigational agents.
• Unresolved toxicity from other agents. Patients with unresolved Common Terminology Criteria for Adverse Events (CTCAE) version (v)4.03 grade 3 or greater toxicity from prior administration of another investigational drug and/or anti-cancer treatment are not eligible.